Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Top Cited Papers
Open Access
- 19 July 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (3), 239-250
- https://doi.org/10.1056/nejmoa062897
Abstract
Certolizumab pegol is a pegylated humanized Fab′ fragment with a high binding affinity for tumor necrosis factor α that does not induce apoptosis of T cells or monocytes.Keywords
This publication has 21 references indexed in Scilit:
- Certolizumab Pegol for the Treatment of Crohn's DiseaseNew England Journal of Medicine, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s DiseaseGastroenterology, 2005
- Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory studyAlimentary Pharmacology & Therapeutics, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Range of antinuclear antibodies in “healthy” individualsArthritis & Rheumatism, 1997
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.Gut, 1991
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990